Abstracts tagged "B cell targeting and Macrophage"

Abstract Number: 2413 • 2019 ACR/ARP Annual Meeting
LOU064: A Highly Selective and Potent Covalent Oral BTK Inhibitor with Promising Pharmacodynamic Efficacy on B Cells for Sjoegren’s Syndrome
Bruno Cenni¹, Peter End ¹, Maciej Cabanski ¹, Annamaria Jakab ¹, Enrico Funhoff ¹, Magdalena Kistowska ¹, Arvind Kinhikar ², Alessio Maiolica ¹, Masaru Hirano ³, Barbara Nuesslein-Hildesheim ¹, Amanda Littlewood-Evans ¹, Daniela Angst ¹, Robert Pulz ⁴ and Martin Kaul ¹, ¹Novartis Institutes for BioMedical Research, Basel, Switzerland, ²Novartis Institutes for BioMedical Research, Cambridge, MA, ³Novartis Institutes for BioMedical Research, Tokyo, Japan, ⁴Novartis Institues for BioMedical Research, Basel, Switzerland
Background/Purpose: Bruton’s Tyrosine Kinase (BTK) is a cytoplasmic tyrosine kinase selectively expressed in B cells, macrophages, mast cells and basophils. The essential role of BTK…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Abstracts tagged "B cell targeting and Macrophage"

LOU064: A Highly Selective and Potent Covalent Oral BTK Inhibitor with Promising Pharmacodynamic Efficacy on B Cells for Sjoegren’s Syndrome